FDA Approves Expanded Label For CANCIDAS(R) As The 1st And Only Echinocandin Therapy For Pediatric Patients With Indicated Fungal Infections

Merck & Co., Inc. announced that the U.S. Food and Drug Administration (FDA) has approved an expanded label for CANCIDAS , which makes it the first and only echinocandin therapy approved in the United States for the treatment of pediatric patients aged 3 months to 17 years with indicated fungal infections....